Medlab Clinical - Novel drug delivery and synthetic cannabinoids
Medlab is a drug delivery biotechnology company with a proprietary platform, NanoCelle, which is a patented nanomicellar formulation that can improve the delivery of drugs. With the growing appreciation of the medicinal properties of cannabis, Medlab-s lead product became NanaBis, a THC:CBD (1:1) cannabis extract encapsulated in NanoCelle particles, which enable a convenient buccal spray delivery. The most recent breakthrough was Medlab-s announcement that it had successfully produced a synthetic version of NanaBis, thus significantly streamlining the regulatory pathway. Once the product reformulation is done (current guidance is eight to 10 months), NanaBis will re-enter clinical development (potentially Phase III) as a fully synthetic, non-opioid pain relief drug optimised with proprietary delivery technology aimed at a vast market.
Washington [US], June 1 (ANI): American TV personality Kelly Osbourne recently opened up about her battles with drug and alcohol addiction. She discussed getting hooked as a teen and relapsing after the pandemic.
Neuren Pharmaceuticals (ASX:NEU) says it has received "clear and constructive guidance" from the US FDA Office of Neuroscience in pre-IND meetings for.
NOXXON Pharma N.V.: Noxxon Announces Manufacturing of NOX-A12 Drug Substance for Future Clinical Trials and Issuance of Convertible Bonds Under Financing Agreement With Atlas
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has received two batches of bulk NOX-A12 drug substance and has made additional manufacturing commitments. As such, NOXXON has drawn down additional financing tranches from its financing agreement with Atlas Special Opportunities, LLC (ASO), for a total consideration of €2.325 million, and issued 2,368 convertible bonds (including 43 convertible bonds issued in relation to the transaction fee) with a nominal value of EUR 1,000 each.